Vifor Pharma establishes Benelux Office in Breda - News - BrIM Breda

Contact info

Postbus 2522

Claudius Prinsenlaan 10

T1 +31 (0)6 22 97 51 82
T2 +31 (0)6 52 81 37 98

Vifor Pharma establishes Benelux Office in Breda

  • Home
  • News
  • Vifor Pharma establishes Benelux Office in Breda
Vifor Pharma establishes Benelux Office in Breda

Vifor Pharma is an originally Swiss company forming the “pharma division” of the Galenica Group, which is active in the pharmaceutical and healthcare sectors. For two years Vifor Pharma had offices in the Netherlands (Utrecht) as well as Belgium (Antwerp) and has now decided to merge these into one Benelux office in Breda. On the short term 25 employees will start their activities for Vifor Pharma from the new office. It mainly concerns jobs in marketing and sales.

After having explored the region for the first time, Mr Geert ter Schure, managing director of Vifor Pharma Nederland BV, immediately found Breda a logical spot to join Vifor Pharma’s forces within the Benelux. “Of course it is already a fine location, geographically, but in Breda we also found other elements that are important to our organisation”, according to Mr Ter Schure. “Aspects such as accessibility, the presence of highly skilled personnel and other pharmaceutical companies tipped the scales. We are looking forward to starting our activities from Breda.

“In spite of, or maybe even thanks to the worldwide economic recession companies keep discovering the advantages of going Benelux”, adds Mr Cees Meeuwis, alderman for Economic Affairs of the City of Breda. “The fact that Breda can offer the optimum location and conditions of establishment  will not do our municipality the worse. The central location, accessibility, - also via HSL from April 2011 – and the favourable level of costs have led to a steady increase of the number of Benelux offices with the additional benefit of extra employment. In this respect Breda stands out on the international map!”, according to alderman Meeuwis.


In fact, Vifor Pharma chose Breda for its central location in the Benelux as well as for the presence of other large pharmaceutical companies like Amgen, UCB Pharma, Kinesis Pharma etc.


Vifor Pharma is the pharma division of the Swiss Galenica Group. Galenica (or „galenics“ is the science active in the method of making medicines) is a diversified group operating within the full spectrum  of the healthcare market. Among other things, it develops, manufactures and sells pharmaceutical products, runs pharmacies, offers logistical and database services and sets up networks. The Galenica Group is divided into two divisions, Pharma and Health, and  the four business units of Pharma, Logistics, Retail and Healthcare Information.

The Vifor Pharma flag unites all the Galenica companies involved in pharmaceutical research and development and in manufacturing and selling pharmaceutical products.

Galenica has approximately 5,500 employees worldwide and in 2009 netted a profit of 210m (roughly € 148m)


Two-pillared Success

Vifor Pharma is a specialised pharmaceutical company, based on two main business units: Rx (prescribed medicine) and Consumer Healthcare (OTC = over the counter, so freely available products). The company’s special aims are research, development, production and marketing of both its own and license-manufactured products against anaemia, kidney diseases and diseases of the auto-immune system.


Furthermore, Vifor Pharma offers a wide range of self-produced, acquired or licence-produced OTC products that are marketed by its own organisation in the larger European countries. Vifor Pharma is growing, as is its global presence. All its products are centrally produced in Switzerland and the United Kingdom, marketing and distribution on the other hand are taken care of by an extensive network of both its own sites and distributors throughout the world.

To realise its business targets, Vifor Pharma regularly closes strategic alliances and joint ventures. For example, Vifor announced on 2nd December last that it will intensify its present cooperation with Fresenius Medical Care (FMC) by jointly setting up a specialised pharmaceutical company in the field of nephrology, the science of kidney diseases. The new organisation will supply innovative and very advanced products to improve the quality of life of people suffering from Chronic Kidney Disease (CKD) worldwide. Among other things, this is done with products called Venofer®  and Ferinject® which are used in dialysis and pre-dialysis (CKD stage III – V) and PA21, a pioneering iron-based phosphate binder.

Posted on 18-01-2011

close window

Email this page

Share this page with a friend by filling out the information below.

Fields marked whit a * are required.

close window

Email this page

The page has successfully been forwarded.